A Decade of Pharmaceutical Innovation and Excellence

Accelerating access to affordable medicines and delivering life-changing healthcare solutions

A Decade of

Accelerating Affordable Medicine

Our commitment to breaking healthcare barriers drives every milestone we have accomplished over the past decade.

Journey with us to discover how ten years of pharmaceutical excellence have translated into better health outcomes for patients worldwide.

2016

Commenced the first high-containment API R&D Centre in ASEAN
Commenced the first Finished Product R&D Centre in ASEAN to develop complex products meeting USFDA standards

2017

Commenced the first high-containment oncology finished product R&D Centre in ASEAN to develop OEB5 products meeting USFDA standards
Pioneered SEA industry benchmarks by delivering first-to-market medicines through non-infringing formulations

2020

Commissioned Novugen Pharma's state-of-the-art Oral Solid Dosage manufacturing facility with NPRA approval

2021

Commissioned Novugen Oncology's state-of-the-art Oral Solid Dosage manufacturing facility with NPRA approval

2022

Attained USFDA approval for Novugen Pharma's manufacturing facility – First in Malaysia and only one in SE Asia
Novugen Oncology's flagship product – Abiraterone Acetate received ANDA approval for US market
Launched Novugen Pharma's first products, Novugab (Pregabalin) and Tadigra (Tadalafil), to all healthcare sectors in Malaysia

2023

Expanded product portfolio across ASEAN markets with 12 new finished dosage formulations launched in Vietnam and Indonesia
Established strategic partnership with leading European generics distributor to enter EU markets
Achieved ISO 14001 certification for sustainable manufacturing practices across all facilities

2024

Secured first exclusive first-to-file status for Trametinib in the US market – a testament to R&D excellence and innovative capabilities
Commissioned new high-potency API manufacturing block in Malaysia with USFDA, EMA, and TGA compliance
Expanded oncology product line with 5 new ANDA filings targeting solid tumor and hematological cancer therapies

2025

Crossed 1,000 Novugenians milestone with operations spanning 18 countries across ASEAN, MENA, LATAM, and now Europe
Launched dedicated R&D Centre of Excellence in Uzbekistan focused on Central Asian therapeutic needs
Partnered with global health initiatives to provide affordable oncology medicines to underserved markets in Africa

2026

Celebrating a decade of pharmaceutical innovation with 300+ products available across 25+ countries worldwide
Inaugurated state-of-the-art biosimilars development facility – first of its kind in Southeast Asia
Achieved milestone of serving over 10,000 hospitals, clinics, and pharmacies globally with life-changing medicines

Over 70 Complex Finished Products

More than 40 Product Launches (Malaysia)

10 ANDA Approvals (USA)

280

280 Products in 13 Countries (ASEAN, MENA, LATAM)

Top 14 Pharmaceutical Company in Malaysia by revenue

5260

Our products span across 5,260 hospitals, clinics, and pharmacies nationwide

A Decade of Impact

Guided by scientific innovation, R&D excellence, and a commitment to challenging the status quo, we continue to push the boundaries of accessible healthcare solutions.

Since 2016, Novugen has grown into a leading pharmaceutical company specializing in niche and difficult-to-formulate generics across multiple therapeutic areas, bringing affordable, life-changing medicines to patients and communities worldwide.

Latest News

28 April 2026

Year In Review 2025 Highlights

25 Sep 2025

Novugen Launched Sacubitril and Valsartan Tablets in the U.S. Following Recent ANDA Approval

14 Aug 2025

Novugen Secured Patent Grant for Amlodipine and Valsartan Process Innovation

30 June 2025

Malaysia at the Forefront of Driving ASEAN's Pharmaceutical Self-Reliance

16 May 2025

Novugen Oncology Receives Approval from UAE MoHAP

17 April 2025

Novugen and Hikma Pharmaceuticals Announce Strategic Partnership

14 Feb 2025

Novugen Strengthens Ties with Uzbekistan's Ministry of Health

31 Dec 2024

Year in Review: Novugen 2024 Highlights

Growing with Novugen

At Novugen, growth is built together. Powered by over 800 Novugenians driving impact around the globe, our people are the driving force behind everything we do. Discover how Novugenians are growing, impacting lives, and shaping the future with Novugen.

Digital biological twins and organoids might sound like sci-fi, but they're real – and we're using them to fight cancer